Back

Resiniferatoxin (RTX) ameliorates acute respiratory distress syndrome (ARDS) in a rodent model of lung injury

Hahka, T. M.; Xia, Z.; Hong, J.; Kitzerow, O.; Nahama, A.; Zucker, I. H.; Wang, H.

2020-09-14 physiology
10.1101/2020.09.14.296731 bioRxiv
Show abstract

Acute lung injury (ALI) is associated with cytokine release, pulmonary edema and in the longer term, fibrosis. A severe cytokine storm and pulmonary pathology can cause respiratory failure due to acute respiratory distress syndrome (ARDS), which is one of the major causes of mortality associated with ALI. In this study, we aimed to determine a novel neural component through cardiopulmonary spinal afferents that mediates lung pathology during ALI/ARDS. We ablated cardiopulmonary spinal afferents through either epidural T1-T4 dorsal root ganglia (DRG) application or intra-stellate ganglia delivery of a selective afferent neurotoxin, resiniferatoxin (RTX) in rats 3 days post bleomycin-induced lung injury. Our data showed that both epidural and intra-stellate ganglia injection of RTX significantly reduced plasma extravasation and reduced the level of lung pro-inflammatory cytokines providing proof of principle that cardiopulmonary spinal afferents are involved in lung pathology post ALI. Considering the translational potential of stellate ganglia delivery of RTX, we further examined the effects of stellate RTX on blood gas exchange and lung edema in the ALI rat model. Our data suggest that intra-stellate ganglia injection of RTX improved pO2 and blood acidosis 7 days post ALI. It also reduced wet lung weight in bleomycin treated rats, indicating a reduction in lung edema. Taken together, this study suggests that cardiopulmonary spinal afferents play a critical role in lung inflammation and edema post ALI. This study shows the translational potential for ganglionic administration of RTX in ARDS.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
American Journal of Physiology-Lung Cellular and Molecular Physiology
39 papers in training set
Top 0.1%
18.5%
2
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.1%
12.4%
3
PLOS ONE
4510 papers in training set
Top 22%
8.4%
4
Scientific Reports
3102 papers in training set
Top 24%
4.8%
5
European Respiratory Journal
54 papers in training set
Top 0.4%
3.9%
6
Respiratory Research
19 papers in training set
Top 0.1%
3.6%
50% of probability mass above
7
The FASEB Journal
175 papers in training set
Top 0.5%
2.6%
8
International Journal of Molecular Sciences
453 papers in training set
Top 4%
2.6%
9
Biomedicines
66 papers in training set
Top 0.5%
2.1%
10
Cell Death Discovery
51 papers in training set
Top 0.4%
2.1%
11
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 1%
1.9%
12
Frontiers in Physiology
93 papers in training set
Top 2%
1.9%
13
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.9%
14
Physiological Reports
35 papers in training set
Top 0.5%
1.7%
15
Journal of Cellular Physiology
21 papers in training set
Top 0.3%
1.5%
16
eLife
5422 papers in training set
Top 49%
1.2%
17
Acta Physiologica
13 papers in training set
Top 0.1%
1.2%
18
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
13 papers in training set
Top 0.2%
0.9%
19
Frontiers in Medicine
113 papers in training set
Top 6%
0.9%
20
Function
15 papers in training set
Top 0.4%
0.9%
21
American Journal of Physiology-Cell Physiology
34 papers in training set
Top 0.3%
0.9%
22
Heliyon
146 papers in training set
Top 6%
0.8%
23
JCI Insight
241 papers in training set
Top 7%
0.7%
24
American Journal of Respiratory and Critical Care Medicine
39 papers in training set
Top 0.9%
0.7%
25
Journal of the Endocrine Society
11 papers in training set
Top 0.4%
0.7%
26
Journal of the American Heart Association
119 papers in training set
Top 4%
0.7%
27
Journal of Internal Medicine
12 papers in training set
Top 0.8%
0.7%
28
Acta Pharmaceutica Sinica B
11 papers in training set
Top 1%
0.7%
29
BioMed Research International
25 papers in training set
Top 3%
0.7%
30
Pharmacology Research & Perspectives
11 papers in training set
Top 0.3%
0.7%